Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × GIST × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 110 Carcinoma, Non-Small-Cell Lung 89 Prostatic Neoplasms 55 Colorectal Neoplasms 48 Nasopharyngeal Carcinoma 43 Neoplasms 40 Stomach Neoplasms 31 Multiple Myeloma 31 Lung Neoplasms 28 Carcinoma, Hepatocellular 26 Neoplasm Metastasis 25 Leukemia, Myeloid, Acute 24 Recurrence 22 Ovarian Neoplasms 22 Rectal Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 20 Pancreatic Neoplasms 20 Uterine Cervical Neoplasms 19 Triple Negative Breast Neoplasms 19 Esophageal Neoplasms 19 Colonic Neoplasms 19 Brain Neoplasms 19 Small Cell Lung Carcinoma 17 Urinary Bladder Neoplasms 15 Lymphoma, Large B-Cell, Diffuse 15 Lymphoma, Follicular 15 Myasthenia Gravis 14 Leukemia, Lymphocytic, Chronic, B-Cell 13 Esophageal Squamous Cell Carcinoma 13 Endometrial Neoplasms 13

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡